Global Health Board Re-appoints Naresh Trehan as CMD, Approves Dividend

Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

Global Health Board Approves Trehan Re-appointment, Dividend

Global Health Limited's board has approved the re-appointment of Dr. Naresh Trehan as Chairman and Managing Director (CMD) and Chairman of Heart Institute & Chief Cardiac Surgeon (CCS) with effect from August 01, 2026. The board has also recommended a final dividend of ₹0.50 per equity share for the financial year ended March 31, 2025.

The decision was taken at the board meeting held on August 07, 2025. The board has also recommended his re-appointment to the shareholders for a further period of five years.

The total remuneration payable to Dr. Trehan in all capacities (CMD & CCS) shall not exceed ₹33.00 Crores for the financial year 2026-27.

The maximum remuneration that can be paid to Dr. Trehan as CMD is ₹8.00 Crores for FY27.

The maximum remuneration that can be paid to Dr. Trehan as CCS is ₹25.00 Crores for FY27.

The total remuneration payable to Dr. Trehan in all capacities (CMD & CCS) shall not exceed ₹36.30 Crores for the financial year 2027-28.

The maximum remuneration that can be paid to Dr. Trehan as CMD is ₹8.80 Crores or 10% increment on the last drawn remuneration whichever is lower for FY28.

The maximum remuneration that can be paid to Dr. Trehan as CCS is ₹27.50 Crores or 10% increment on the last drawn remuneration whichever is lower for FY28.

The total remuneration payable to Dr. Trehan in all capacities (CMD & CCS) shall not exceed ₹39.95 Crores for the financial year 2028-29.

The maximum remuneration that can be paid to Dr. Trehan as CMD is ₹9.70 Crores or 10% increment on the last drawn remuneration whichever is lower for FY29.

The maximum remuneration that can be paid to Dr. Trehan as CCS is ₹30.25 Crores or 10% increment on the last drawn remuneration whichever is lower for FY29.

The total remuneration payable to Dr. Trehan in all capacities (CMD & CCS) shall not exceed ₹44.20 Crores for the financial year 2029-30.

The maximum remuneration that can be paid to Dr. Trehan as CMD is ₹10.70 Crores or 10% increment on the last drawn remuneration whichever is lower for FY30.

The maximum remuneration that can be paid to Dr. Trehan as CCS is ₹33.50 Crores or 10% increment on the last drawn remuneration whichever is lower for FY30.

The total remuneration payable to Dr. Trehan in all capacities (CMD & CCS) shall not exceed ₹48.50 Crores for the financial year 2030-31.

The maximum remuneration that can be paid to Dr. Trehan as CMD is ₹11.50 Crores or 10% increment on the last drawn remuneration whichever is lower for FY31.

The maximum remuneration that can be paid to Dr. Trehan as CCS is ₹37.00 Crores or 10% increment on the last drawn remuneration whichever is lower for FY31.

Dr. Trehan's current remuneration for financial year 2025-26 is ₹7.20 Crores as CMD and ₹22.63 Crores as Chairman - Heart Institute & Chief Cardiac Surgeon (CCS) as approved by the Board of Directors on May 15, 2025.

The shareholders had approved an upper cap of ₹35.00 Crores on total remuneration including remuneration of ₹7.50 Crores as CMD.

The Board has also re-appointed Mr. Vikram Singh Mehta and Mr. Hari Shanker Bhartia as an Independent Director for a second term of 5 years.

The board approved the re-appointment of M/s MAKS & Co., Company Secretaries as Secretarial Auditor of the Company for the first term of 5 years, to conduct Secretarial Audit and other certifications as required.

The board has also recommended the approval of remuneration payable to Cost Auditors, with M/s. Ramanath Iyer & Co. appointed as Cost Auditors for FY26 at a fee of ₹11.50 Lakhs.

The 21st Annual General Meeting (AGM) of the Company will be held on Friday, September 19, 2025.

The board has recommended a final dividend of ₹0.50 per equity share for the financial year ended March 31, 2025. The record date fixed for determining the entitlement of the members to the final dividend is August 22, 2025.

The board has also approved the appointment of a Director in place of Mr. Ravi Kant Jaipuria, who retires by rotation and being eligible, offers himself for re-election.

Notice of the 21st Annual General Meeting (AGM), scheduled to be held on Friday, September 19, 2025, at 12 Noon (IST), through Video Conferencing (VC)/Other Audio Visual Means (OAVM), in accordance with the relevant circulars issued by the Ministry of Corporate Affairs (MCA) and Securities and Exchange Board of India (SEBI), from time to time. The said Notice of AGM is also available on the Company's website i.e. https://www.medanta.org/investor-relation

The remote e-voting period begins on Monday, September 15, 2025 at 09:00 A.M. and ends on Thursday, September 18, 2025 at 05:00P.M.

The board has approved the re-appointment of Dr. Naresh Trehan as Chairman and Managing Director (CMD) and Chairman of Heart Institute & Chief Cardiac Surgeon (CCS) with effect from August 01, 2026.